Insights

The best patient support programs simplify enrolment and product access while making it easy for healthcare providers to access data about the patient’s journey. Yet there's been little innovation in the PSP space to date. Get healthcare provider perspectives on how to optimize patient support programs for chronic disease.

In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?

What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.

The high-touch, high-quality, personalized care independent pharmacies provide creates a unique value proposition in a healthcare market where more chronically ill patients need accessible care. As payers are prioritizing improved patient outcomes and a reduction in overall healthcare costs, they need to also consider new reimbursement models for these pharmacy services, a framework under which independent pharmacies are uniquely positioned to excel.

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

What information do payers and providers want from pharma?

How are payers thinking about apps, wearables and other digital health technologies?

Understanding the unique considerations for reimbursement in the Canadian pharmaceutical market.

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.

Like a slowly dripping faucet or an improperly insulated window, gaps and inefficiencies in a business allow profits to seep out over time. Even one leak—while seemingly small—can have damaging effects on a company’s financial health. Oncology practices are no different.